$ALNY

AI Analysis

Generated on May 11, 2026

AI Score
68/ 100
Hold$ALNY

Alnylam Pharmaceuticals

$ALNYNASDAQHealthcareLarge-Cap

Alnylam pioneers RNAi therapeutics for genetic diseases with Onpattro, Givlaari, and Oxlumo.

Market Cap
$32.0B
Revenue (TTM)
$2.5B
+45.0%
Net Income (TTM)
$0.1B
N/A
EPS (TTM)
$0.50
P/E Ratio
N/A
Dividend Yield
0.0%
52-Week Range
$150-$270
Beta
0.72
Dimension Scores
Fundamental
60
Technical
64
Sentiment
74
Risk / Reward
58
Momentum
78
FundTechSentRiskMome
Financial Health
Profitability
65moderate
Growth
81strong
Liquidity
66strong
Solvency
62moderate
Efficiency
58moderate

Valuation, technical analysis, investment thesis, risk assessment and more for $ALNY

Free · No credit card required

Disclaimer: AI-generated analysis for educational purposes only. Not financial advice. Always consult a qualified financial advisor.

Explore more

Analyze any stock with AI

Get a structured equity research report covering fundamentals, technicals, sentiment, risk, and investment thesis — in about 60 seconds.